Profil bibliographique

Luca Maurillo

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

295Publications signalées

8022Citations signalées

4Affiliations récentes

Institutions déclarées

University of Rome Tor Vergata Policlinico Tor Vergata Ospedale Santa Maria Goretti Sapienza University of Rome

Domaines associés

Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia Treatments

Publications récentes

Accès ouvert 2026 articleOpenAlex

Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial

Luca Maurillo, Francesco Buccisano, Raffaele Palmieri, Marta Cipriani et autres

0 citationsAmerican Journal of Hematology

Accès ouvert 2026 articleOpenAlex

Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study

Luca Guarnera, Giuseppe Gaetano Loscocco, Massimo Breccia, Mara Memoli et autres

0 citationsClinical and Experimental Medicine

2026 articleOpenAlex

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Raffaele Palmieri, Alfonso Piciocchi, Stefano Soddu, Marco Frigeni et autres

0 citationsBritish Journal of Haematology

2026 articleOpenAlex

De novo JAK2 ‐mutated acute myeloid leukaemia: Clinical outcomes and molecular features

Luca Guarnera, Emiliano Fabiani, Eleonora Lumia, Paola Ricci et autres

0 citationsBritish Journal of Haematology

Accès ouvert 2026 articleOpenAlex

Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia

Fabio Efficace, Laura Cannella, Xavier Thomas, Meltem Kurt Yüksel et autres

0 citationsThe Oncologist

Accès ouvert 2026 articleOpenAlex

Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex‐Stratified Analysis of the GIMEMA AML1310 Trial

Lorella Maria Antonia Melillo, Valentina Arena, Alfonso Piciocchi, A. Candoni et autres

0 citationsAmerican Journal of Hematology

Accès ouvert 2026 articleOpenAlex

Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients

Elisa Buzzatti, Cristina Mauro, Cristiano Tesei, Giovangiacinto Paterno et autres

0 citationsCancers

Accès ouvert 2026 articleOpenAlex

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort

Calogero Vetro, Irene Azzali, Elisabetta Petracci, Cristina Papayannidis et autres

0 citationsHematological Oncology

Accès ouvert 2025 preprintOpenAlex

Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients

Elisa Buzzatti, Cristina Mauro, Cristiano Tesei, Giovangiacinto Paterno et autres

0 citationsPreprints.org

Accès ouvert 2025 articleOpenAlex

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

Jacqueline Cloos, Peter J.M. Valk, Christian Thiede, Konstanze Döhner et autres

56 citationsBlood

Accès ouvert 2025 articleOpenAlex

Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

Lukas H. Haaksma, Raffaele Palmieri, Tom Reuvekamp, Jesse M. Tettero et autres

1 citationLeukemia

Accès ouvert 2025 articleOpenAlex

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Elisabetta Petracci, Francesca Pavesi, Luca Castagna, Patrizia Zappasodi et autres

0 citationsBritish Journal of Haematology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.